This approval allows for at-home administration in patients 6-11 years old with severe eosinophilic asthma. PHILADELPHIA, PA, 24 January 2022 — GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has…Original Article
FDA Approves Nucala (mepolizumab) 40 mg Prefilled Syringe for Children with Severe Eosinophilic Asthma
